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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The objective is to assess the effects of complete withdrawal of at least one antihypertensive medication on cognitive function in healthy
and cognitive impaired adults.
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B A C K G R O U N D
Hypertension (blood pressure above a recommended value) is a
common clinical condition with a well-established causal role in
cardiovascular disease(Lewington 2002). Hypertension is particu-
larly prevalent in older age; more than half of the population over
the age of 50 years, and approximately 80% of the population old-
er than 80 years have hypertension (Chow 2013; Cohen 2011). The
protective effect of antihypertensive treatment against cardiovas-
cular events and premature mortality is well established (Law 2009;
Musini 2009). The evidence to support treatment of hypertension in
healthy older adults is robust (Beckett 2012). Evidence for benefit
of antihypertensive therapy in frail older adults with comorbidities
and geriatric syndromes including cognitive and functional decline
is limited, and some data suggest potential for harm, with stud-
ies describing association between antihypertensive therapy and
higher mortality (Benetos 2015), and serious injuries arising from
falls (Tinetti 2014).
The evidence for antihypertensive therapy in those with cognitive
impairment or dementia, and the impact of this treatment on cog-
nition is uncertain, with conflicting results in published data and
no meta-analysis possible due to heterogeneity (Beishon 2014).
Data have variously shown a protective, harmful or neutral effect
of antihypertensives on cognition. A study with almost 5000 older
adults, suggested no detrimental effect of antihypertensive treat-
ment on cognitive function in people with existing cognitive prob-
lems (Skoog 2005). Two other large studies did not show a reduc-
tion of incident dementia in patients treated with antihypertensive
medications (Di Bari 2001; Peters 2008). However, other work has
suggested a protective effect of antihypertensive treatment on vas-
cular induced dementia (Tzourio 2003), while another study report-
ed potential for antihypertensive medication to accelerate cogni-
tive decline (Alrawi 2013).
These seemingly conflicting trial data may be explained by the
complex relationship between blood pressure and cognition over
the life course. Hypertension in middle-age is a risk factor for inci-
dent dementia, driven at least in part by cerebrovascular disease
(Norton 2014). However, the association between blood pressure
and dementia at an older age is inverse (Kennelly 2009; Qiu 2009).
Several years before dementia onset, a decrease in blood pressure
can be seen (Skoog 1996), and low blood pressure is associated
with cognitive decline in the years after diagnosis (Nilsson 2007),
although the direction of causality is unknown. Several mecha-
nisms have been proposed to underlie this decrease in blood pres-
sure in the years before the diagnosis of dementia, including auto-
nomic dysregulation as symptom of neurodegeneration (den Abee-
len 2014). The arteriosclerotic and age-related changes to cerebral
blood flow autoregulation in older people could also result in cere-
bral hypoperfusion, potentially influencing cognitive functioning
(Qiu 2009).
Thus, the evidence base for cognitive benefits of hypertension
treatment in midlife is compelling, but the evidence for cognitive
effects of hypertension treatment in older age is less clear. The
Cochrane systematic review on hypertension treatment in the el-
derly showed that adherence to treatment is limited and a con-
siderable proportion of older patients discontinue treatment, due
to adverse effects, in particular when the level of prescribed treat-
ment increased (Musini 2009) . Taking all this into account, there is
a concern that antihypertensive medication may have potential for
harm in those with cognitive impairment/dementia and it may neg-
atively influence cognitive functioning. There has been associated
debate regarding the benefit of withdrawing antihypertensive ther-
apy in older adults, since the risk-benefit ratio of treatment might
be different at differing ages and with different classes of antihy-
pertensive medications (Shah 2009).
It would be interesting for policymakers if withdrawal of hyper-
tensive medications has a positive effect on cognitive functioning,
since this might possibly lead to a decrease in dementia incidence
and thus major health cost savings. Reducing medication use will
also contribute to less healthcare expenditures.
The purpose of this systematic review is to summarise all avail-
able evidence on cognitive effects of withdrawal of antihyperten-
sive medications and associated benefits and harms in adults (in-
cluding healthy adults and those with prevalent cognitive decline).
Description of the condition
We will focus on the implications of antihypertensive medication
on cognitive functioning, including cognitive decline and demen-
tia. Cognitive decline is often accompanied by deterioration in
emotional control, social behaviour, or motivation. The number of
people living with cognitive impairment not classified as dementia
is probably even higher, but no exact data on this exist. The term
‘dementia’ refers to a group of diseases which shares a syndrome
that is typically chronic and progressive in nature. The dementia
syndrome involves disturbances of multiple higher cortical func-
tions, such as memory, thinking, orientation, perception and be-
haviour, which are severe enough to affect the ability to perform
everyday activities. The number of people living with dementia is
increasing due to the ageing world population. Currently, world-
wide 47.5 million people are estimated to be affected. This number
will double within the next 20 years, resulting in high costs and con-
siderable burden to individuals and societies (WHO 2015).
Description of the intervention
In this review we will identify and appraise controlled clinical trials
which evaluate the cognitive consequences of withdrawal of anti-
hypertensive treatment in adults.
How the intervention might work
There are plausible theoretical reasons why withdrawal of antihy-
pertensive therapy may have a beneficial effect on cognition, most-
ly relating to improving cerebral perfusion. Equally, withdrawal of
antihypertensive therapy may accelerate cognitive decline through
incident stroke or progression of small vessel disease.
Interventions to completely withdraw at least one antihypertensive
medication in patients with and without cognitive problems may
also reduce adverse effects and improve quality of life for the pa-
tient and carer. However, they may also cause withdrawal symp-
toms like “rebound” tachycardia with withdrawal of beta-blocker,
headache, agitation and nausea (Karachalios 2005). We will there-
fore examine trials which evaluate effects of antihypertensive with-
drawal, contributing to the evidence base in this area.
Why it is important to do this review
Contemporary guidelines for blood pressure management in old-
er adults focus on indications for treatment and choice of treat-
ment. There is ground to suspect that withdrawal of antihyperten-
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sive medication in certain older adult populations may have bene-
ficial effects on cognition and/or rate of dementia. A cost saving in-
tervention (drug withdrawal) that impacts on cognition would have
important individual and public health implications. A synthesis of
all relevant data will move us closer to adopting evidence based in-
terventions, or will identify the evidence gaps that require further
original research. In general, studies that address the effect of with-
drawal of drugs in (frail) older populations are highly relevant to
prevent unnecessary and potentially harmful treatments.
O B J E C T I V E S
The objective is to assess the effects of complete withdrawal of
at least one antihypertensive medication on cognitive function in
healthy and cognitive impaired adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will select studies if they meet the following criteria: ran-
domised controlled trials (RCTs) comparing withdrawal of antihy-
pertensive medications with continuation of the medications. We
will also include controlled clinical trials (CCTs) that meet other in-
clusion criteria. An outcome measure assessing cognitive function
or dementia diagnosis must be clearly defined.
Types of participants
Participants must be aged 18 years and over. Participants must
have been taking the antihypertensive medications for a minimum
of one month irrespective of indication.
Participants may reside in any healthcare setting (including acute
hospitals, nursing and residential homes and the community). We
will include healthy participants and participants with all grades of
severity of dementia or cognitive impairment.
Types of interventions
Withdrawal of any medication with blood pressure lowering effects
(see list of relevant medications included in Appendix 1) with no re-
striction to duration of follow-up.
Types of outcome measures
Primary outcomes• Cognitive impairment or rates of incident dementia in healthy
and cognitive impaired adults• Cognition in the short-term in adults with or without established
cognitive impairment.
Cognitive function quantified with a recognised multidomain as-
sessment instrument, for example (but not limited to) Folstein's Mi-
ni Mental State Examination (MMSE) (Folstein 1975), Montreal Cog-
nitive Assessment (MoCA) (Nasreddine 2005), more extensive neu-
ropsychological testing, or formal clinical diagnosis of dementia ac-
cording to current internationally accepted guidelines, for example
(but not limited to) International Classification of Diseases and Re-
lated Health Problems (ICD-10), Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV).
Secondary outcomes• Effects on systolic and diastolic blood pressure.• Adherence to withdrawal of the antihypertensive medications.
We will define adherence to withdrawal as patients remain-
ing oG medication for the duration of the study or at least six
months, whichever is longer.• Rates of serious adverse events across the included studies.
Including mortality, cardiovascular events, early (within first 8
weeks) and late (post-six months) adverse effects (e.g. falls and
hospitalisation).
Search methods for identification of studies
We will use the electronic databases listed below to search for rele-
vant studies regardless of language, personnel, research setting or
date of publication.
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois) - the Cochrane
Dementia and Cognitive Improvement Group's (CDCIG) specialised
register.
ALOIS is maintained by the Trials Search Co-ordinator for the CD-
CIG, and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy older adult populations. The studies are
identified through:
1. monthly searches of a number of major healthcare databases:
MEDLINE, EMBASE, CINAHL, PsycINFO and LILACS;
2. monthly searches of a number of trial registers: ISRCTN; UMIN
(Japan's Trial Register); the World Health Organization (WHO)
portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese
Clinical Trials Register; the German Clinical Trials Register; the
Iranian Registry of Clinical Trials and the Netherlands National
Trials Register, plus others);
3. quarterly search of the Cochrane Central Register of Controlled
Trials (CENTRAL); and
4. six-monthly searches of a number of grey literature sources: ISI
Web of Knowledge Conference Proceedings; Index to Theses;
Australasian Digital Theses.
To view a list of all sources searched for ALOIS see AboutALOIS on
the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed in
the ‘methods used in reviews’ section within the editorial infor-
mation about the Cochrane Dementia and Cognitive Improvement
Group.
We will run additional searches in MEDLINE, EMBASE, PsycINFO,
CINAHL, LILACS, Web of Science core collection, ClinicalTrials.gov
and the WHO Portal/ICTRP to ensure that the search is as compre-
hensive and as up-to-date as possible. The search strategy that we
will use to retrieve reports of trials from MEDLINE (via the Ovid SP
platform) can be seen in Appendix 2.
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Searching other resources
In case of incomplete reports, we will conduct further searches for
connected papers, or we will contact authors to retrieve missing in-
formation.
We will handsearch the reference lists of all of the relevant articles
that we retrieve and search for non-MEDLINE listed journals. We
will also search the Science Citation Index for articles citing key ref-
erences. We will contact authors of relevant papers and relevant
organisations to identify additional studies, including unpublished
and ongoing studies. Finally, we will revise key original database
search strategies based on the yield of the above searches and up-
date for subsequent reviews.
Data collection and analysis
Selection of studies
Phase 1: Two review authors (SJ and JH) will perform searches
and screening of identified studies independently. We will indepen-
dently examine titles and abstracts of citations obtained from the
searches and discard obviously irrelevant articles. At this stage, we
will be overly inclusive; we will retrieve for further assessment of
any article that suggests a relevant trial.
Phase 2: From the potentially relevant articles in Phase I, two re-
view authors (SJ and JH) will independently select trials (based on
the full-text format) for inclusion. We will resolve disagreement on
study inclusion by consensus or third party adjudication.
We will detail the study selection process in a PRISMA flow diagram
(Moher 2009).
Data extraction and management
Two independent review authors (SJ and JH) will perform data ex-
traction using a prespecified data extraction form and enter the da-
ta into Review Manager software (RevMan 2014).
Assessment of risk of bias in included studies
At least two independent review authors (SJ and JH) will assess
the internal validity of each included study. Where relevant details
are unclear, we will ask for clarification and we will discuss dis-
crepancies with a third reviewer (ER), if necessary. We will use the
Cochrane 'Risk of bias' tool for assessment and we will use sev-
en standard criteria: random sequence generation; allocation con-
cealment; blinding of participants and personnel; blinding of out-
come assessment; incomplete outcome data; selective reporting;
other risk of bias (Higgins 2011). We will assess every study for each
of the seven criteria and report the information in a 'Risk of bias'
table.
We will restrict the primary analysis to studies at low or unclear risk
of bias. We will perform sensitivity analyses to determine how con-
clusions might be affected if studies at high risk of bias are added
to the analysis.
Measures of treatment e8ect
In the first instance we will present a narrative description of stud-
ies and results; if data allow we will perform a meta-analysis to de-
scribe summary effects.
The meta-analysis will require the combination of data from trials
that may not use the same rating scale or test to assess an outcome.
The measure of the withdrawal of treatment difference for any out-
come will be the weighted mean difference when the pooled trials
use the same assessment instrument, and the standardised mean
difference when different assessment instruments are used. For bi-
nary outcomes we will use the odds ratio (OR) to measure treat-
ment effect and calculate a weighted estimate of the typical treat-
ment effect across trials.
Unit of analysis issues
We will consider for each study whether groups of individuals were
randomised together to the same intervention (i.e. cluster-ran-
domised trials), whether individuals underwent more than one in-
tervention (e.g. in a cross-over trial, or simultaneous treatment of
multiple sites on each individual) or whether there are multiple ob-
servations for the same outcome (e.g. repeated measurements, re-
curring events).
Dealing with missing data
We will contact authors of studies if there are missing data cru-
cial for the interpretation or the use in quantitative meta-analysis
and we will report this. We will make a qualitative judgement as to
whether to exclude studies if the impact of missing data is too large.
Assessment of heterogeneity
We will only perform a meta-analysis when studies are sufficient-
ly homogeneous in terms of participants, interventions and out-
comes. Statistical heterogeneity will be considered by using the I2
test (Higgins 2011). We will consider heterogeneity of 30% to 60%
as moderate, 50% to 90% as substantial and 75% to 100% as con-
siderable. We will make a decision on the appropriateness of meta-
analysis based on statistical and clinical heterogeneity.
Assessment of reporting biases
We will search for non-published as well as published studies in
databases and trial registries, to avoid publication bias. To avoid
language bias, we will not employ language restrictions for includ-
ed studies. Where there are multiple publications from one study,
we will only include the primary publication to address duplicate
publication bias. To investigate the likelihood of overt publication
bias, we will enter data from all identified trials into a funnel plot.
Data synthesis
We will decide on suitability of meta-analysis for each outcome by
a qualitative assessment (including statistical and clinical hetero-
geneity) of the included studies.
We will conduct data synthesis and analyses using Review Manag-
er software (RevMan 2014). We will use risk ratios (RRs) and a ran-
dom-effects model to combine outcomes across trials for a meta-
analysis. The weighting factor for each study is the inverse of the
within-study variance plus a between-study variance component.
If it is not possible to combine outcome data due to differences in
the reporting or substantive heterogeneity, we will report a narra-
tive summary.
Study duration of trials may vary. If the range of study duration is
considered too large to pool all trials into one meta-analysis, we
will divide the data into smaller time periods and conduct a sepa-
rate meta-analysis for each period. Some trials may contribute da-
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ta to more than one time period if multiple assessments have been
made.
Subgroup analysis and investigation of heterogeneity
If around 10 or more trials are identified that contribute to the
analyses of primary outcomes, we aim to perform stratified analy-
ses of the primary effectiveness outcome, according to the follow-
ing trial characteristics: presence versus absence of dementia or
cognitive impairment at baseline, age, type of antihypertensive
treatment (thiazide diuretics, ACE inhibitors, etc.).
Data presentation - 'Summary of findings' tables
We will use the GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) approach to assess the quality of
the supporting evidence behind each estimate of treatment ef-
fect (Schunemann 2011a; Schunemann 2011b) . We will present
key findings of the review including a summary of the amount
of data, the magnitude of the effect size and the overall quality
of the evidence, in a 'Summary of findings' table, created using
GRADEproGDT software (GRADEproGDT 2015). We have preselect-
ed the following outcomes: cognitive impairment (1. incident de-
mentia (clinical diagnosis) and 2. change in a validated cognitive
test score); change in systolic and diastolic blood pressure; mortal-
ity; cardiovascular events; falls; hospitalisation and re-commence-
ment of antihypertensive medications.
Sensitivity analysis
We will perform a sensitivity analysis for pooled results based on
methodological quality if possible. Many issues suitable for a sen-
sitivity analysis can only be identified during the review process
when the individual peculiarities of studies under investigation are
identified. We will perform sensitivity analyses without possibly in-
cluded CCTs to look at the effect of these studies and to avoid risk
of bias.
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A P P E N D I C E S
Appendix 1. All medications with antihypertensive function (irrespective of indication)
Loop diuretics: bumetanide, ethacrynic acid, furosemide, torsemide
Thiazide diuretics: epitizide, hydrochlorothiazide and chlorothiazide, bendroflumethiazide, xipamide
Thiazide-like diuretics: indapamide, chlorthalidone, metolazone
Potassium-sparing diuretics: amiloride, triamterene
Dihydropyridines: amlodipine, cilnidipine, felodipine, isradipine, lercanidipine, levamlodipine, nicardipine, nifedipine, nimodipine, ni-
trendipine, barnidipine, lacidipine, aranidipine, azelnidipine, benidipine, clevidipine, darodipine, efonidipine, manidipine, niguldipine,
nilvadipine, nisoldipine, nitrendipine, oxodipine, pranidipine
Non-dihydropyridines: diltiazem, verapamil
ACE-inhibitors: captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril, benazepril, zofenopril, imidapril,
cilazapril
Angiotensin II receptor antagonists: candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, azilsartan, fimasar-
tan
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Beta blockers: atenolol, metoprolol, nadolol, nebivolol, oxprenolol, pindolol, propranolol, timolol, bisoprolol, acebutolol, celiprolol, es-
molol, sotalol
Alpha blockers: doxazosin, phentolamine, indoramin, phenoxybenzamine, prazosin, terazosin, tolazolin, ketanserin, urapidil, fentolamin
Mixed Alpha + Beta blockers: carvedilol, labetalol
Vasodilators: hydralazine, minoxidil
Renin Inhibitors: aliskiren
Aldosterone receptor antagonists: eplerenone, spironolactone
Alpha-2 adrenergic receptor agonists: clonidine, guanabenz, guanfacine, methyldopa, moxonidine, guanethidine, mecamylamine
Other: magnesium sulfate
Appendix 2. MEDLINE search strategy
1 exp Antihypertensive Agents/
2 Hypertension/dt
3 antihypertensive*.ti,ab.
4 anti-hypertensive*.ti,ab.
5 exp Angiotensin-Converting Enzyme Inhibitors/
6 exp Angiotensin Receptor Antagonists/
7 angiotensin converting enzyme inhibitor*.ti,ab.
8 (ace adj2 inhibitor*).ti,ab.
9 (acei or ace-i).ti,ab.
10 Angiotensin II/ai [Antagonists & Inhibitors]
11 (angiotensin adj2 receptor antagonist*).ti,ab.
12 (angiotensin adj2 receptor block*).ti,ab.
13 AT 2 receptor block*.ti,ab.
14 AT 2 receptor antagon*.ti,ab.
15 (ARB or ARBs).tw.
16 exp Adrenergic beta-Antagonists/
17 exp Adrenergic alpha-Antagonists/
18 exp Diuretics/
19 adrenergic beta antagonist*.ti,ab.
20 adrenergic alpha antagonist*.ti,ab.
21 beta block*.ti,ab.
22 41. alpha block*.ti,ab.
23 diuretic*.ti,ab.
24 exp Calcium Channel Blockers/
25 calcium channel blocker*.ti,ab.
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26 (CCB or CCBs).ti,ab.
27 chlorothiazide.ti,ab.
28 Chlorothiazide/
29 chlorthalidone.ti,ab.
30 Chlorthalidone/
31 hydralazine.ti,ab.
32 Hydralazine/
33 hydrochlorothiazide.ti,ab.
34 Hydrochlorothiazide/
35 minoxidil.ti,ab.
36 Minoxidil/
37 captopril.ti,ab.
38 Captopril/
39 enalapril.ti,ab.
40 Enalapril/
41 fosinopril.ti,ab.
42 Fosinopri/
43 lisinopril.ti,ab.
44 Lisinopril/
45 ramipril.ti,ab.
46 Ramipril/
47 losartan.ti,ab.
48 Losartan/
49 irbesartan.ti,ab.
50 irbesartan /
51 candesartan.ti,ab.
52 eprosartan.ti,ab.
53 valsartan.ti,ab.
54 olmesartan.ti,ab.
55 telmisartan.ti,ab.
56 amlodipine.ti,ab.
57 diltiazem.ti,ab.
58 felodipine.ti,ab.
59 nicardipine.ti,ab.
60 nifedipine.ti,ab.
Antihypertensive withdrawal for the prevention of cognitive decline (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
61 nimodipine.ti,ab.
62 verapamil.ti,ab.
63 alprenolol.ti,ab.
64 atenolol.ti,ab.
65 metoprolol.ti,ab.
66 nadolol.ti,ab.
67 oxprenolol.ti,ab.
68 pindolol.ti,ab.
69 propranolol.ti,ab.
70 labetalol.ti,ab.
71 prazosin.ti,ab.
72 spironolactone.ti,ab.
73 triamterene.ti,ab.
74 bumetanide.ti,ab.
75 furosemide.ti,ab.
76 indapamide.ti,ab.
77 frusemide.ti,ab.
78 diazoxide.ti,ab.
79 eplerenone.ti,ab.
80 amiloride.ti,ab.
81 clonidine.ti,ab.
82 methyldopa.ti,ab.
83 isradipine.ti,ab.
84 xipamide.ti,ab.
85 barnidipine.ti,ab.
86 lacidipine.ti,ab.
87 aranidipine.ti,ab.
88 azelnidipine.ti,ab.
89 benidipine.ti,ab.
90 clevidipine.ti,ab.
91 darodipine.ti,ab.
92 efonidipine.ti,ab.
93 manidipine.ti,ab.
94 niguldipine.ti,ab.
95 nilvadipine.ti,ab.
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96 nisoldipine.ti,ab.
97 nitrendipine.ti,ab.
98 oxodipine.ti,ab.
99 pranidipine.ti,ab.
100 zofenopril.ti,ab.
101 imidapril.ti,ab.
102 cilazapril.ti,ab.
103 azilsartan.ti,ab.
104 fimasartan.ti,ab.
105 bisoprolol.ti,ab.
106 acebutolol.ti,ab.
107 celiprolol.ti,ab.
108 esmolol.ti,ab.
109 sotalol.ti,ab.
110 ketanserin.ti,ab.
111 urapidil.ti,ab.
112 fentolamin.ti,ab.
113 minoxidil.ti,ab.
114 magnesium sulphate.ti,ab.
115 or/1-114
116 withdraw*.mp.
117 cessat*.mp.
118 (reduce* OR reducing* OR reduct*).mp.
119 taper*.mp.
120 stop*.mp.
121 (“carr* on” OR continuation).mp.
122 (“come oG” OR “taken off”).mp.
123 or/116-122
124 randomised controlled trial.pt.
125 controlled clinical trial.pt.
126 random*.ab.
127 placebo.ab.
128 drug therapy.fs.
129 trial.ab.
130 groups.ab.
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131 “double-blind*”.ti,ab.
132 “single-blind*”.ti,ab.
133 or/124-132
134 114 and 123 and 133
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